Cardiovascular Health
Cannabinoid effects on the heart and vasculature
Cannabis use has measurable acute cardiovascular effects — primarily tachycardia and blood pressure variability mediated by THC's CB1 agonism in the autonomic nervous system. For most healthy adults these effects are transient, but for patients with pre-existing cardiovascular disease the risk profile is meaningfully elevated. CBD, by contrast, shows vasodilatory and potentially cardioprotective properties in preclinical models, though robust human RCT data remain limited.
What the Research Shows
The cardiovascular effects of cannabinoids are primarily mediated through CB1 receptors in the heart and vasculature, as well as indirect sympathetic nervous system activation. Acute THC exposure causes a dose-dependent increase in heart rate (10–100% above baseline), transient hypertension followed by orthostatic hypotension, and increased myocardial oxygen demand. These effects are particularly concerning in patients with coronary artery disease, heart failure, or arrhythmia. Epidemiological data link heavy cannabis use with increased risk of myocardial infarction, stroke, and cannabis-associated arteritis, though confounding by tobacco co-use complicates interpretation. CBD's cardiovascular profile is more favorable: preclinical studies demonstrate anti-inflammatory, antioxidant, and vasodilatory effects, and one human RCT found CBD reduced resting blood pressure and attenuated stress-induced cardiovascular responses. The endocannabinoid system also plays a role in cardiac remodeling and ischemia-reperfusion injury, representing a potential therapeutic target.
Key Findings
THC acutely increases heart rate by 20–100%
Well-StudiedCB1-mediated sympathetic activation causes dose-dependent tachycardia within minutes of exposure, lasting 1–3 hours. Tolerance develops with chronic use.
Cannabis use associated with increased MI risk in young adults
Well-StudiedEpidemiological studies find 1.5–4.8x elevated MI risk in the hour after cannabis use, particularly in those with pre-existing cardiovascular risk factors.
CBD reduces resting blood pressure in humans
Emerging ResearchA double-blind crossover RCT found a single 600mg CBD dose reduced resting systolic BP by 6mmHg and attenuated stress-induced BP increases.
Cannabis-associated arteritis is a rare but serious complication
Limited EvidenceCase series document cannabis-associated arteritis affecting distal limb arteries, clinically resembling Buerger's disease, predominantly in young male users.
Endocannabinoid system modulates cardiac ischemia-reperfusion injury
Limited EvidencePreclinical models show CB2 receptor activation reduces infarct size and inflammatory response after ischemia-reperfusion, suggesting therapeutic potential.
Featured Studies
View all in libraryCommon Questions
What We Still Don't Know
These are open research questions — areas where the evidence is insufficient or actively contested.
- 1Does long-term CBD use have a meaningful antihypertensive effect in hypertensive patients?
- 2What is the cardiovascular risk profile of vaporized cannabis vs. smoked cannabis?
- 3Do CB2 receptor agonists have cardioprotective effects in human ischemia-reperfusion injury?
- 4Is there a safe THC dose threshold for patients with stable coronary artery disease?
- 5Does the cardiovascular risk of cannabis use differ by genetic CB1 receptor polymorphisms?
- 6What is the mechanism of cannabis-associated arteritis, and how does it differ from Buerger's disease?